MedPath

Xofigo

These highlights do not include all the information needed to use XOFIGO safely and effectively. See full prescribing information for XOFIGO. XOFIGO (radium Ra 223 dichloride) injection, for intravenous useInitial U.S. Approval: 2013

Approved
Approval ID

a398400e-bd31-41a9-9696-4f7c06569ede

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 10, 2019

Manufacturers
FDA

Bayer HealthCare Pharmaceuticals Inc.

DUNS: 005436809

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Radium Ra 223 dichloride

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code50419-208
Application NumberNDA203971
Product Classification
M
Marketing Category
C73594
G
Generic Name
Radium Ra 223 dichloride
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateMay 24, 2017
FDA Product Classification

INGREDIENTS (5)

SODIUM CHLORIDEInactive
Code: 451W47IQ8X
Classification: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT
RADIUM RA-223 DICHLORIDEActive
Quantity: 30 uCi in 1 mL
Code: RJ00KV3VTG
Classification: ACTIB
SODIUM CITRATE, UNSPECIFIED FORMInactive
Code: 1Q73Q2JULR
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Xofigo - FDA Drug Approval Details